International Duchenne Alliance Annual Meeting
Posted by: Christine McSherry on January 25, 2013
"Advancing our missions to improve the quality of life, care and treatment of those affected by Duchenne".
Pledge made by Duchenne Alliance members in 2011
Join us -
International Duchenne Alliance
Annual Conference March 7th – 10, 2013
Le Meridien Hotel, Cambridge, Massachusetts
March 7, 2013 - Thursday - WELCOME
3:00 pm - Children's Hospital Life Sciences Center - Lab Tour with Dr. Lou Kunkel
6:00 pm - Sarepta Cocktail Reception at Sarepta Therapeutics, Cambridge Massachusetts
March 8, 2013 - Friday - DAY 1
8:30 pm - 5:00 PM, Non Profit Management and Infrastructure
Guest-speakers, work shops and sharing of best practices for Duchenne organizations.
7:00 pm - Group Dinner - TBA
March 9, 2013 - Saturday - DAY 2
8:30 am - 5:00 pm, Co-Identify and Co-Fund Opportunities, Connect, and Speed Science
Presentations from a variety of researchers.
March 10, 2013 -
10:00 AM, Executive Board Meeting
Conference Fee: $350 per person, DUE MARCH 1, 2013, payable to Jett Foundation, 68 Evergreen Street, Suite One, Kingston, MA 02364.
Includes breakfast and lunch on both days, as well as Alliance member group dinner on Friday March 8, 2013 only, at the Le Meridien.
*Does not include accommodations or transportation.
Accommodations - Le Meridien, be sure to mention your Duchenne Alliance affiliation.
Ground Transportation - Try our friends at Uber!
Uber is your on demand private driver. Download this app to your smartphone before you arrive.
Your alliance teammates await your participation.
Not an alliance member, consider joining – together we will move further, faster.
Bookmark the permalink | Tagged alliance, dmd, duchenne, Duchenne Alliance, muscular dystrophy
pdufa fda patient-directed drug development patient perspectives duchenne muscular dystrophy harrison's fund duchenne allinace duchenne research alliance international invitation meeting duchenne muscular dystophy dmd treatment exon skipping sarepta eteplirsen dmd Permissible Risk Patient Perspective Duchenne Alliance PDUFA-V Fast Track Accelerated Approval Priority Review IND NDA Breakthrough therapy exon-skipping Duchenne muscular dystrophy collaboration rigorous review higher resolution. duchenne advocacy treatments pfizer children's hospital boston srpt $srpt jett foundation gower test biotech cambridge becker forbes healthcare rare disease new york times boston daily news prosensa moms morpholinos team community congress race to yes obama washington dc racetoyes washington white house petition fox business fox news stossel willis report government